2024
Limitations in Achieving Glycemic Targets From CGM Data and Persistence of Severe Hypoglycemia in Adults With Type 1 Diabetes Regardless of Insulin Delivery Method
Laffel L, Sherr J, Liu J, Wolf W, Bispham J, Chapman K, Finan D, Titievsky L, Liu T, Hagan K, Gaglia J, Chandarana K, Pettus J, Bergenstal R. Limitations in Achieving Glycemic Targets From CGM Data and Persistence of Severe Hypoglycemia in Adults With Type 1 Diabetes Regardless of Insulin Delivery Method. Diabetes Care 2024, 48: 273-278. PMID: 39699995, PMCID: PMC11770157, DOI: 10.2337/dc24-1474.Peer-Reviewed Original ResearchDaily glucose variability is associated with intrahepatic fat content, β cell sensitivity, and biomarkers of glycolysis in youth with obesity
Barbieri E, Bonet J, Fox D, Nelson R, Nelson M, Nelson L, Fernandez C, Van Name M, Samuels S, Caprio S, Sabati M, Galderisi A, Sherr J, Man C, Santoro N. Daily glucose variability is associated with intrahepatic fat content, β cell sensitivity, and biomarkers of glycolysis in youth with obesity. Obesity 2024, 33: 116-124. PMID: 39658509, PMCID: PMC11666407, DOI: 10.1002/oby.24175.Peer-Reviewed Original ResearchConceptsIntrahepatic fat contentDaily glucose variabilityLiver proton density fat fractionProton density fat fractionGlucose variabilityInsulin sensitivityOral glucose tolerance testFat fractionInsulin secretionAssociated with insulin resistanceFirst-phase insulin secretionAssociated with 2-h glucoseGlucose tolerance testGlucose standard deviationMagnetic resonance imagingOral minimal modelCoefficient of variationBasal insulin secretionPediatric obesityPostprandial glucoseTolerance testCell sensitivityInsulin resistanceObesityResonance imagingThe use of automated insulin delivery around physical activity and exercise in type 1 diabetes: a position statement of the European Association for the Study of Diabetes (EASD) and the International Society for Pediatric and Adolescent Diabetes (ISPAD)
Moser O, Zaharieva D, Adolfsson P, Battelino T, Bracken R, Buckingham B, Danne T, Davis E, Dovč K, Forlenza G, Gillard P, Hofer S, Hovorka R, Jacobs P, Mader J, Mathieu C, Nørgaard K, Oliver N, O’Neal D, Pemberton J, Rabasa-Lhoret R, Sherr J, Sourij H, Tauschmann M, Yardley J, Riddell M. The use of automated insulin delivery around physical activity and exercise in type 1 diabetes: a position statement of the European Association for the Study of Diabetes (EASD) and the International Society for Pediatric and Adolescent Diabetes (ISPAD). Diabetologia 2024, 68: 255-280. PMID: 39653802, PMCID: PMC11732933, DOI: 10.1007/s00125-024-06308-z.Peer-Reviewed Original ResearchConceptsEuropean Association for the Study of DiabetesPhysical activityInternational Society for Pediatric and Adolescent DiabetesType 1 diabetesRegular physical activityPosition statementDiabetes careStudy of DiabetesClinical practice pointsResponse to PAManaged PAsEuropean Association for the StudyHealth benefitsAge groupsExerciseAdolescent DiabetesAutomated insulin deliveryDiabetesInsulin deliveryGlucose target rangeTherapy optionsClinical trialsDeliveryGlucose levelsCareReal-World Evidence of Automated Insulin Delivery System Use
Considine E, Sherr J. Real-World Evidence of Automated Insulin Delivery System Use. Diabetes Technology & Therapeutics 2024, 26: 53-65. PMID: 38377315, PMCID: PMC10890954, DOI: 10.1089/dia.2023.0442.Peer-Reviewed Original ResearchConceptsGlucose management indicatorAid useRetrospective real-world studyMode of insulin deliveryGlycemic benefitsFollow-up periodTrial findingsFood and Drug AdministrationStandard of careReal-world studyInsulin deliveryType 1 diabetesNonpregnant individualsPivotal trialsRetrospective analysisPrimary outcomeHemoglobin A1cConclusion:</i></b>Drug AdministrationInclusion criteriaHbA1cGlycemic outcomesSystematic reviewResults:</i></b>Target rangePostprandial Glucose Variability Following Typical Meals in Youth Living with Type 1 Diabetes
Patton S, Bergford S, Sherr J, Gal R, Calhoun P, Clements M, Riddell M, Martin C. Postprandial Glucose Variability Following Typical Meals in Youth Living with Type 1 Diabetes. Nutrients 2024, 16: 162. PMID: 38201991, PMCID: PMC10781146, DOI: 10.3390/nu16010162.Peer-Reviewed Original ResearchConceptsGlycemic variabilityGlucose variabilityType 1Continuous glucose monitoringPediatric studiesCarbohydrate intakeDay observation periodMacronutrient intakeDietary guidelinesPhysical activityExercise intensityT1DGlucose monitoringObservation periodTypical mealMeal contentMealIntakeCoefficient of variationAssociationMacronutrient contentMore carbohydratesCliniciansLarge sample
2023
Two Years with a Tubeless Automated Insulin Delivery System: A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 Diabetes
Criego A, Carlson A, Brown S, Forlenza G, Bode B, Levy C, Hansen D, Hirsch I, Bergenstal R, Sherr J, Mehta S, Laffel L, Shah V, Bhargava A, Weinstock R, MacLeish S, DeSalvo D, Jones T, Aleppo G, Buckingham B, Ly T, Group F. Two Years with a Tubeless Automated Insulin Delivery System: A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics 2023, 26: 11-23. PMID: 37850941, PMCID: PMC10794844, DOI: 10.1089/dia.2023.0364.Peer-Reviewed Original ResearchConceptsAdolescents/adultsPivotal trialsInsulin delivery systemsSingle-arm multicenter trialYears of useClinical trial registrationType 1 diabetesLong-term safetyMonths of useLong-term useDiabetic ketoacidosisMulticenter trialSevere hypoglycemiaTRIAL REGISTRATIONGlycemic outcomesType 1Delivery systemExtension phaseMonthsTrialsTarget rangeAdultsHbA1cChildrenEpisodesThe Acute Effects of Real-World Physical Activity on Glycemia in Adolescents With Type 1 Diabetes: The Type 1 Diabetes Exercise Initiative Pediatric (T1DEXIP) Study.
Riddell M, Gal R, Bergford S, Patton S, Clements M, Calhoun P, Beaulieu L, Sherr J. The Acute Effects of Real-World Physical Activity on Glycemia in Adolescents With Type 1 Diabetes: The Type 1 Diabetes Exercise Initiative Pediatric (T1DEXIP) Study. Diabetes Care 2023, 47: 132-139. PMID: 37922335, DOI: 10.2337/dc23-1548.Peer-Reviewed Original ResearchConceptsReal-world physical activityPhysical activityType 1Pediatric studiesHeart rateLower baseline HbA1c levelsReal-world observational studySelf-reported physical activityBaseline HbA1c levelsShorter disease durationPeak heart rateType 1 diabetesSelf-management strategiesDisease durationHbA1c levelsMedian durationLess hypoglycemiaLower BMIAcute effectsContinuous glucose monitoring dataObservational studyFood intakeEvent-level factorsInsulin dosingActive adolescentsSafety and Glycemic Outcomes During the MiniMedTM Advanced Hybrid Closed-Loop System Pivotal Trial in Children and Adolescents with Type 1 Diabetes
Pihoker C, Shulman D, Forlenza G, Kaiserman K, Sherr J, Thrasher J, Buckingham B, Kipnes M, Bode B, Carlson A, Lee S, Latif K, Liljenquist D, Slover R, Dai Z, Niu F, Shin J, Jonkers R, Roy A, Grosman B, Vella M, Cordero T, McVean J, Rhinehart A, Vigersky R, Bode B, Buckingham B, Carlson A, Casaubon L, Christiansen M, Cordero T, Garg S, Grosman B, Kaiserman K, Kipnes M, Latif K, Lee S, Liljenquist D, Lintereur L, Liu M, McVean J, Parikh N, Peng F, Pihoker C, Philis-Tsimikas A, Pop-Busui R, Reed J, Rhinehart A, Roy A, Sherr J, Shin J, Shulman D, Singh K, Slover R, Thrasher J, Vella M, Vigersky R, Wu D. Safety and Glycemic Outcomes During the MiniMedTM Advanced Hybrid Closed-Loop System Pivotal Trial in Children and Adolescents with Type 1 Diabetes. Diabetes Technology & Therapeutics 2023, 25: 755-764. PMID: 37782145, DOI: 10.1089/dia.2023.0255.Peer-Reviewed Original ResearchConceptsDiabetic ketoacidosisSensor glucosePivotal trialsSevere hypoglycemiaPredictive low glucose managementSingle-arm studySensor-augmented pumpType 1 diabetesEnd of studyMean sensor glucoseEffectiveness endpointTreat populationGlycemic targetsGlucose targetsInvestigational centersPrimary safetyGlycemic outcomesMean TIRA1CType 1Higher TIRStudy periodClosed-loop useCoefficient of variationLower TBRSecond international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine
Tobias D, Merino J, Ahmad A, Aiken C, Benham J, Bodhini D, Clark A, Colclough K, Corcoy R, Cromer S, Duan D, Felton J, Francis E, Gillard P, Gingras V, Gaillard R, Haider E, Hughes A, Ikle J, Jacobsen L, Kahkoska A, Kettunen J, Kreienkamp R, Lim L, Männistö J, Massey R, Mclennan N, Miller R, Morieri M, Most J, Naylor R, Ozkan B, Patel K, Pilla S, Prystupa K, Raghavan S, Rooney M, Schön M, Semnani-Azad Z, Sevilla-Gonzalez M, Svalastoga P, Takele W, Tam C, Thuesen A, Tosur M, Wallace A, Wang C, Wong J, Yamamoto J, Young K, Amouyal C, Andersen M, Bonham M, Chen M, Cheng F, Chikowore T, Chivers S, Clemmensen C, Dabelea D, Dawed A, Deutsch A, Dickens L, DiMeglio L, Dudenhöffer-Pfeifer M, Evans-Molina C, Fernández-Balsells M, Fitipaldi H, Fitzpatrick S, Gitelman S, Goodarzi M, Grieger J, Guasch-Ferré M, Habibi N, Hansen T, Huang C, Harris-Kawano A, Ismail H, Hoag B, Johnson R, Jones A, Koivula R, Leong A, Leung G, Libman I, Liu K, Long S, Lowe W, Morton R, Motala A, Onengut-Gumuscu S, Pankow J, Pathirana M, Pazmino S, Perez D, Petrie J, Powe C, Quinteros A, Jain R, Ray D, Ried-Larsen M, Saeed Z, Santhakumar V, Kanbour S, Sarkar S, Monaco G, Scholtens D, Selvin E, Sheu W, Speake C, Stanislawski M, Steenackers N, Steck A, Stefan N, Støy J, Taylor R, Tye S, Ukke G, Urazbayeva M, Van der Schueren B, Vatier C, Wentworth J, Hannah W, White S, Yu G, Zhang Y, Zhou S, Beltrand J, Polak M, Aukrust I, de Franco E, Flanagan S, Maloney K, McGovern A, Molnes J, Nakabuye M, Njølstad P, Pomares-Millan H, Provenzano M, Saint-Martin C, Zhang C, Zhu Y, Auh S, de Souza R, Fawcett A, Gruber C, Mekonnen E, Mixter E, Sherifali D, Eckel R, Nolan J, Philipson L, Brown R, Billings L, Boyle K, Costacou T, Dennis J, Florez J, Gloyn A, Gomez M, Gottlieb P, Greeley S, Griffin K, Hattersley A, Hirsch I, Hivert M, Hood K, Josefson J, Kwak S, Laffel L, Lim S, Loos R, Ma R, Mathieu C, Mathioudakis N, Meigs J, Misra S, Mohan V, Murphy R, Oram R, Owen K, Ozanne S, Pearson E, Perng W, Pollin T, Pop-Busui R, Pratley R, Redman L, Redondo M, Reynolds R, Semple R, Sherr J, Sims E, Sweeting A, Tuomi T, Udler M, Vesco K, Vilsbøll T, Wagner R, Rich S, Franks P. Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine. Nature Medicine 2023, 29: 2438-2457. PMID: 37794253, PMCID: PMC10735053, DOI: 10.1038/s41591-023-02502-5.Peer-Reviewed Original ResearchConceptsDiabetes medicinesInternational Consensus ReportPrecision diabetes medicineContemporary evidence-based medicineSystematic evidence reviewEvidence-based medicineHealth equityConsensus reportHealth recommendationsPrecision medicine researchEvidence reviewPrecision medicineClinical readinessLife-threatening complicationsPillars of precision medicineRisk of complicationsMedical decisionsClinically relevant evidenceRelevant evidenceClinical presentationMedicine researchHealthRevealed opportunitiesOptimal outcomesDiabetesOGTT Metrics Surpass Continuous Glucose Monitoring Data for T1D Prediction in Multiple-Autoantibody–Positive Individuals
Ylescupidez A, Speake C, Pietropaolo S, Wilson D, Steck A, Sherr J, Gaglia J, Bender C, Lord S, Greenbaum C. OGTT Metrics Surpass Continuous Glucose Monitoring Data for T1D Prediction in Multiple-Autoantibody–Positive Individuals. The Journal Of Clinical Endocrinology & Metabolism 2023, 109: 57-67. PMID: 37572381, PMCID: PMC10735531, DOI: 10.1210/clinem/dgad472.Peer-Reviewed Original ResearchConceptsContinuous glucose monitoringClinical trialsPositive individualsOral glucose tolerance testPrediction of T1DGlucose tolerance testType 1 diabetesCGM dataTrialNet PathwayMultiple autoantibodiesT1D diagnosisTolerance testAncillary studiesContinuous glucose monitoring dataMultivariable modelCGM metricsInsufficient evidenceAcademic centersGlucose monitoring dataHigh discriminative abilityT1D predictionGlucose monitoringCGM measuresCharacteristic curveOGTTGlycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor
Cordero T, Dai Z, Arrieta A, Niu F, Vella M, Shin J, Rhinehart A, McVean J, Lee S, Slover R, Forlenza G, Shulman D, Pop-Busui R, Thrasher J, Kipnes M, Christiansen M, Buckingham B, Pihoker C, Sherr J, Kaiserman K, Vigersky R, Group F. Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor. Diabetes Technology & Therapeutics 2023, 25: 652-658. PMID: 37252734, PMCID: PMC10460682, DOI: 10.1089/dia.2023.0123.Peer-Reviewed Original ResearchImpact of school‐supervised ultra‐long‐acting basal insulin injections on ketosis in youth with T1D and elevated haemoglobin A1c: A pilot study
Nally L, Sherr J, Tichy E, Weyman K, Urban A, Shabanova V, McCollum S, Steffen A, Tamborlane W, Van Name M. Impact of school‐supervised ultra‐long‐acting basal insulin injections on ketosis in youth with T1D and elevated haemoglobin A1c: A pilot study. Diabetic Medicine 2023, 40: e15123. PMID: 37078999, PMCID: PMC10524154, DOI: 10.1111/dme.15123.Peer-Reviewed Original ResearchConceptsBasal insulin injectionsDiabetic ketoacidosisPercent of participantsBlood β-hydroxybutyrateInsulin injectionsBasal insulin dosesBasal insulin typeType 1 diabetesManagement of youthDegludec groupSignificant ketosisAcute complicationsBasal insulinInsulin dosesRisk of ketosisInjected insulinHigher hemoglobinInsulin administrationElevated hemoglobinInsulin typeKetone levelsHigh riskSchool nursesDegludecLarger sample sizeAnswering clinically pertinent questions with real-world data from paediatric type 1 diabetes registries
Galderisi A, Sherr J. Answering clinically pertinent questions with real-world data from paediatric type 1 diabetes registries. The Lancet Diabetes & Endocrinology 2023, 11: 300-301. PMID: 37004711, DOI: 10.1016/s2213-8587(23)00085-2.Commentaries, Editorials and LettersCGM Metrics Identify Dysglycemic States in Participants From the TrialNet Pathway to Prevention Study.
Wilson D, Pietropaolo S, Acevedo-Calado M, Huang S, Anyaiwe D, Scheinker D, Steck A, Vasudevan M, McKay S, Sherr J, Herold K, Dunne J, Greenbaum C, Lord S, Haller M, Schatz D, Atkinson M, Nelson P, Pietropaolo M. CGM Metrics Identify Dysglycemic States in Participants From the TrialNet Pathway to Prevention Study. Diabetes Care 2023, 46: 526-534. PMID: 36730530, PMCID: PMC10020029, DOI: 10.2337/dc22-1297.Peer-Reviewed Original ResearchConceptsOral glucose tolerance testNormal oral glucose tolerance testType 1 diabetesDiabetes-related autoantibodiesGlucose levelsCGM metricsTrialNet PathwayPrevention StudyAbnormal oral glucose tolerance testGlucose valuesGlucose tolerance testContinuous glucose monitoring parametersStage 2 participantsRelatives of individualsCGMS assessmentDysglycemic statesTolerance testIdentification of individualsDiabetesNegative testAutoantibodiesProgressionBaseline dataIndividualsParticipantsDiabetes Technology Meeting 2022
Huang J, Yeung A, DuBord A, Wolpert H, Jacobs P, Lee W, Drincic A, Spanakis E, Sherr J, Prahalad P, Fleming A, Hsiao V, Kompala T, Lal R, Fayfman M, Ginsberg B, Galindo R, Stuhr A, Chase J, Najafi B, Masharani U, Seley J, Klonoff D. Diabetes Technology Meeting 2022. Journal Of Diabetes Science And Technology 2023, 17: 1085-1120. PMID: 36704821, PMCID: PMC10347991, DOI: 10.1177/19322968221148743.Peer-Reviewed Case Reports and Technical NotesConceptsDiabetes technologyPainful diabetic neuropathyDiabetic foot ulcersSpinal cord stimulationContinuous glucose monitoringElectronic health recordsDiabetic neuropathyFoot ulcersCord stimulationDiabetes careInsulin delivery systemsInsulin pensMeasurement of glucoseGlucose monitor dataGlucose monitoringInsulin deliveryHealth recordsContinuous glucose monitor dataNovel insulinInsulinDelivery systemDigital healthNeuropathyHypoglycemiaUlcers
2022
ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery
Sherr J, Schoelwer M, Dos Santos T, Reddy L, Biester T, Galderisi A, van Dyk J, Hilliard M, Berget C, DiMeglio L. ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery. Pediatric Diabetes 2022, 23: 1406-1431. PMID: 36468192, DOI: 10.1111/pedi.13421.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAutomated insulin delivery: benefits, challenges, and recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association
Sherr JL, Heinemann L, Fleming GA, Bergenstal RM, Bruttomesso D, Hanaire H, Holl RW, Petrie JR, Peters AL, Evans M. Automated insulin delivery: benefits, challenges, and recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association. Diabetologia 2022, 66: 3-22. PMID: 36198829, PMCID: PMC9534591, DOI: 10.1007/s00125-022-05744-z.Peer-Reviewed Original ResearchConceptsAmerican Diabetes AssociationStudy of DiabetesDiabetes AssociationEuropean AssociationConsensus reportClinical careInsulin pumpInsulin deliveryIntensive insulin therapyType 1 diabetesManagement of diabetesRegulatory approvalContinuous glucose monitoringWorking GroupInsulin therapyInsulin delivery systemsDiabetesGlucose monitoringGlucose dataInternal review processAssociationSensor glucose dataCareReportGroupAutomated Insulin Delivery: Benefits, Challenges, and Recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association.
Sherr JL, Heinemann L, Fleming GA, Bergenstal RM, Bruttomesso D, Hanaire H, Holl RW, Petrie JR, Peters AL, Evans M. Automated Insulin Delivery: Benefits, Challenges, and Recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association. Diabetes Care 2022, 45: 3058-3074. PMID: 36202061, DOI: 10.2337/dci22-0018.Peer-Reviewed Original ResearchConceptsAmerican Diabetes AssociationStudy of DiabetesDiabetes AssociationEuropean AssociationConsensus reportClinical careInsulin pumpInsulin deliveryIntensive insulin therapyType 1 diabetesManagement of diabetesRegulatory approvalContinuous glucose monitoringWorking GroupInsulin therapyInsulin delivery systemsDiabetesGlucose monitoringGlucose dataInternal review processAssociationSensor glucose dataCareReportGroupWhen insulin isn’t enough: targeting glucagon in type 1 diabetes
Van Name M, Sherr J. When insulin isn’t enough: targeting glucagon in type 1 diabetes. Nature Medicine 2022, 28: 2007-2008. PMID: 36192555, DOI: 10.1038/s41591-022-02019-3.Commentaries, Editorials and LettersSeeking Simpler Solutions with Diabetes Technology
Sherr J. Seeking Simpler Solutions with Diabetes Technology. New England Journal Of Medicine 2022, 387: 1228-1229. PMID: 36170505, DOI: 10.1056/nejme2210686.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply